Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Deciphera Pharmaceuticals Inc (NQ: DCPH )

8.420 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Deciphera Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of... 
From Business Wire News Releases
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that... 
Tags Pharma/Biotech Market News Stocks / Equities
From TalkMarkets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week endingJan. 21, with the sector retreating along with the broader market. The ... 
Tags ABT DCPH News
From Benzinga
First Week of DCPH July 15th Options Trading
Investors in Deciphera Pharmaceuticals Inc (DCPH) saw new options become available this week, for the July 15th expiration. One of the key data points that goes into the price an option buyer is... 
Tags Stocks
From Market News Video
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate... 
From Business Wire News Releases
Analysts See 25% Gains Ahead For FYC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on... 
From Business Wire News Releases
Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the United... 
From Business Wire News Releases
Deciphera: Why There Won’t Be a Quick Recovery
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Traders might look at DCPH stock for a quick bounce after its 75% decline. But here's why that's not a great idea. The post Deciphera: Why... 
Tags DCPH Hot Stocks NASDAQ:DCPH
From InvestorPlace
Analysts Forecast 25% Upside For The Holdings of FYC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
691 Stocks Are Down Over 50% This Year
It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date. 
Tags Stocks / Equities Market News
From TalkMarkets
Why Deciphera Pharmaceuticals Shot 12% Higher Today
The company announced a comprehensive restructuring program. 
Tags Market News Recent Press Releases DCPH
From Motley Fool
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor... 
Tags NASDAQ:DCPH Market News Stocks to Sell
From InvestorPlace
Deciphera Pharma Stock Rises After Announcing Corporate Restructuring
Deciphera Pharmaceuticals Inc(NASDAQ: DCPH) will undergo acorporate restructuring to eliminate 35% of its workforceand ... 
Tags Long Ideas Movers Benzinga
From Benzinga
Don’t Bet on a Deciphera Stock Comeback
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Qinlock's potential is severely limited, and the rest of Deciphera's pipeline is far from the commercialization stage. With this, expect... 
Tags NASDAQ:DCPH,NYSE:SF SF Market News
From InvestorPlace
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced a corporate... 
From Business Wire News Releases
Deciphera's Qinlock Approved In Europe For Gastric Cancer
TheEuropean Commission has approvedDeciphera Pharmaceuticals Inc's(NASDAQ: DCPH) Qinlock (ripretinib)for adult ... 
Tags Trading Ideas Biotech Small Cap
From Benzinga
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the... 
From Business Wire News Releases
Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip. The post... 
Tags NASDAQ:DCPH Market News Stocks to Sell
From InvestorPlace
What 6 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
Analysts have provided the following ratings for Deciphera Pharmaceuticals (NASDAQ:DCPH) within the last quarter: ... 
Tags Market News Analyst Ratings Benzinga
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ:NKTR), Benchmark upgraded the previous rating of Hold to Buy. Nektar ... 
Tags FICO HSC ACMR
From Benzinga
10 Biggest Price Target Changes For Monday
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) price target from $50 to $11. Deciphera Pharmaceuticals shares rose ... 
Tags CAKE TS Market News
From Benzinga
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public ... 
Tags BTTX Penny Stocks RANI
From Benzinga
Noteworthy Friday Option Activity: DCPH, HUBG, EXPE
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Deciphera Pharmaceuticals Inc (DCPH), where a total volume of 17,914 contracts has... 
Tags Stocks
From Market News Video
Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 0.57% to 36,331.86 while the NASDAQ rose 0.20% to 15,972.41. The S&P also rose, ... 
Tags GDYN Market News MYNZ
From Benzinga
DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows. The... 
Tags NASDAQ:DCPH Market News Today's Market
From InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. ... 
Tags ENDP EVAX Intraday Update
From Benzinga
Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet
Midway through trading Friday, the Dow traded up 0.65% to 36,358.13 while the NASDAQ rose 0.48% to 16,016.51. The S&P also rose, ... 
Tags DCPH News BIGC
From Benzinga
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 ... 
Tags AMEH Mid/Day Movers ASRT
From Benzinga
Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs
Following the market opening Friday, the Dow traded up 0.84% to 36,429.04 while the NASDAQ rose 0.68% to 16,049.24. The S&P also ... 
Tags OTRK Small Cap Markets
From Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.